0.11
0.00%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Avicanna
Its shares trade on Toronto Stock Exchange under the ticker AVCN.TO. It has been listed since 18 July 2019. In the fiscal year to 31 December 2025, it reported revenue of C$25.5m and a net loss of C$2.8m. At that date it held total assets of C$21.2m and shareholders' equity of C$2.8m.
Avicanna, Inc. is a medical cannabis company, which intends to engage in the business of discovery and development processes, intellectual property portfolio, strategic relationships, and cultivation infrastructure. The company is headquartered in Toronto, Ontario. The company went IPO on 2019-07-18. The firm is focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments. In addition to its developing pharmaceutical pipeline, it has product lines, including Pura H&W and RHO Phyto. Pura H&W is a line of cannabidiol (CBD) consumer derma-cosmetic products. RHO Phyto is a line of medical cannabis products containing varying ratios of CBD and tetrahydrocannabinol (THC). The firm's subsidiary includes Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 18 Jul 2019
- Employees
- 19
- Website
- avicanna.com ↗
Leadership
Pay as last reported
- Mr. Aras AzadianChief Executive Officer, Director, since 2016C$579,024
- Mr. Nick HilbornInterim Chief Financial Officer
- Ms. Ivana MaricExecutive Vice President - MarketingC$368,600
- Dr. Karolina UrbanExecutive Vice President - Medical AffairsC$310,372
- Mr. Stephen KimChief Legal Officer, General Counsel & Corporate Secretary of Avicanna USA Inc.C$592,221
- Mr. Giancarlo CharDirectorC$39,900
- Mr. Michael KottDirector
- Ms. Eileen MccormackIndependent DirectorC$63,159
- John McVicarIndependent DirectorC$75,799
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Avicanna Inc has a strong research and development team, allowing them to develop innovative cannabis-based products. This expertise gives them a competitive edge in the rapidly growing cannabis industry.
- The company has secured key partnerships with reputable institutions, such as universities and research organizations. This collaboration enhances Avicanna's credibility and provides access to valuable resources.
- Avicanna has a diverse product portfolio, offering a range of cannabis-based treatments and therapies for various medical conditions. This diversification helps mitigate risks associated with dependence on a single product or market segment.
Weaknesses
- Avicanna Inc faces regulatory challenges in some regions where cannabis remains illegal. This limits market opportunities and may hinder the growth potential of the company.
- The company relies heavily on external funding to support its operations and research activities. This dependence on financing could add financial risks and uncertainties in the long term.
- Avicanna has limited brand recognition compared to some well-established players in the cannabis industry. Building a strong brand image and customer loyalty could be a challenge for the company.
Opportunities
- The legalization of cannabis for medical and/or recreational use in various countries represents a significant growth opportunity for Avicanna. Expanding into new markets could drive revenue growth and market share.
- Avicanna can leverage its research expertise to develop innovative cannabis-based products that cater to evolving consumer demands. This allows the company to stay ahead in a competitive market and attract a wider customer base.
- The increasing acceptance and awareness of the potential medical benefits of cannabis present an opportunity for Avicanna to collaborate with healthcare professionals and expand into the pharmaceutical industry.
Threats
- Intense competition within the cannabis industry poses a threat to Avicanna's market position. Competitors with greater resources and market presence may outperform the company in attracting customers and securing partnerships.
- Changes in government regulations, especially regarding the legal status of cannabis and its derivatives, can have a significant impact on Avicanna's operations. Adapting to evolving regulatory environments requires agility and flexibility.
- The potential negative perception of cannabis-based products by the public or medical professionals could hinder the widespread adoption and acceptance of Avicanna's offerings, limiting market growth.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.